Edwards Lifesciences Is Focusing On Heart Therapy with EVOQUE & SAPIEN M3 — Will It Pay Off?

Edwards Lifesciences reported its third-quarter 2025 financial results, showcasing a strong performance with a 12.6% year-over-year increase in sales, reaching $1.55 billion. This growth was primarily driven by the company’s diverse structural heart portfolio, which includes transcatheter aortic valve replacement (TAVR), transcatheter mitral and tricuspid therapies (TMTT), and surgical innovations. The results exceeded expectations, prompting Edwards Lifesciences to raise its full-year sales growth guidance to the higher end of its previous range of 9% to 10% and adjusted earnings per share estimate to between $2.56 and $2.62. The TAVR segment, one of the company’s key growth drivers, experienced a 10.6% increase in global sales, totaling $1.15 billion for the quarter. This growth reflects expanded evidence and new guidelines, emphasizing the importance of timely intervention for aortic stenosis. Geographically, both the U.S. and international markets contributed significantly, with a stable competitive landscape assisting in steady pricing.